This study provides direct experimental evidence that PNU-282987 can reduce psoriatic inflammation by inhibiting the activation of the STAT3 and NF-κB signal pathways, thereby inhibiting Th17-related immune responses in psoriasis. The gene discussed is STAT3; the disease is psoriasis.